Search Results - "Dezentjé, Vincent"

Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial by van Ramshorst, Mette S, van der Voort, Anna, van Werkhoven, Erik D, Mandjes, Ingrid A, Kemper, Inge, Dezentjé, Vincent O, Oving, Irma M, Honkoop, Aafke H, Tick, Lidwine W, van de Wouw, Agnes J, Mandigers, Caroline M, van Warmerdam, Laurence J, Wesseling, Jelle, Vrancken Peeters, Marie-Jeanne T, Linn, Sabine C, Sonke, Gabe S

“…The optimal chemotherapy backbone for dual HER2 blockade in the neoadjuvant setting for early breast cancer is unknown. We investigated whether the addition of…”
Get full text

Prognostic Value of Novel Liquid Biomarkers in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide: A Prospective Observational Study by Benoist, Guillemette E, van Oort, Inge M, Boerrigter, Emmy, Verhaegh, Gerald W, van Hooij, Onno, Groen, Levi, Smit, Frank, de Mol, Pieter, Hamberg, Paul, Dezentjé, Vincent O, Mehra, Niven, Gerritsen, Winald, Somford, Diederik M, van Erp, Nielka P H, Schalken, Jack A

“…Abstract Background Several treatment options were recently added for metastatic castration-resistant prostate cancer (mCRPC). However, response to therapy is…”
Get full text

Treatment sequences and survival outcomes in advanced HR + HER2- breast cancer patients: a real-world cohort by Almekinders, Cornelia A. M., Lin, Lishi, Beijnen, Jos H., Sonke, Gabe S., Huitema, Alwin D. R., Dezentjé, Vincent O.

“…Abstract Purpose Palliative treatment options for HR + HER2- advanced breast cancer (ABC) patients have increased, but data is lacking about the optimal…”
Get full text

Tamoxifen Pharmacogenetics and Metabolism: Results From the Prospective CYPTAM Study by Sanchez-Spitman, Anabel, Dezentjé, Vincent, Swen, Jesse, Moes, Dirk Jan A R, Böhringer, Stefan, Batman, Erdogan, van Druten, Edith, Smorenburg, Carolien, van Bochove, Aart, Zeillemaker, Anneke, Jongen, Lynn, Los, Maartje, Neven, Patrick, Gelderblom, Hans, Guchelaar, Henk-Jan

“…Tamoxifen is widely prescribed as adjuvant therapy in patients with early-stage breast cancer. It has been postulated that concentrations of endoxifen, the…”
Get full text

Adjuvant chemotherapy in small node-negative triple-negative breast cancer by Steenbruggen, Tessa G., van Werkhoven, Erik, van Ramshorst, Mette S., Dezentjé, Vincent O., Kok, Marleen, Linn, Sabine C., Siesling, Sabine, Sonke, Gabe S.

“…Recommendations on adjuvant chemotherapy in pT1N0M0 triple-negative breast cancer (TNBC) differ among international guidelines owing to lack of randomized…”
Get full text

Exposure–Response Analyses of Olaparib in Real-Life Patients with Ovarian Cancer by Mohmaed Ali, Ma Ida, Bruin, Maaike A. C., Dezentjé, Vincent O., Beijnen, Jos H., Steeghs, Neeltje, Huitema, Alwin D. R.

“…Background Olaparib is given in a fixed dose of twice-daily 300 mg in patients who are diagnosed with ovarian cancer, breast cancer, prostate cancer or…”
Get full text

Effect of Concomitant CYP2D6 Inhibitor Use and Tamoxifen Adherence on Breast Cancer Recurrence in Early-Stage Breast Cancer by DEZENTJE, Vincent O, VAN BLIJDERVEEN, Nico J. C, GELDERBLOM, Hans, PUTTER, Hein, VAN HERK-SUKEL, Myrthe P. P, CASPARIE, Mariel K, EGBERTS, Antoine C. G, NORTIER, Johan W. R, GUCHELAAR, Henk-Jan

“…The use of cytochrome P450 2D6-inhibiting drugs (CYP2D6 inhibitors) during tamoxifen treatment leads to a decrease in plasma concentration of endoxifen, the…”
Get full text

DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis by Henricks, Linda M, Lunenburg, Carin A T C, de Man, Femke M, Meulendijks, Didier, Frederix, Geert W J, Kienhuis, Emma, Creemers, Geert-Jan, Baars, Arnold, Dezentjé, Vincent O, Imholz, Alexander L T, Jeurissen, Frank J F, Portielje, Johanna E A, Jansen, Rob L H, Hamberg, Paul, ten Tije, Albert J, Droogendijk, Helga J, Koopman, Miriam, Nieboer, Peter, van de Poel, Marlène H W, Mandigers, Caroline M P W, Rosing, Hilde, Beijnen, Jos H, Werkhoven, Erik van, van Kuilenburg, André B P, van Schaik, Ron H N, Mathijssen, Ron H J, Swen, Jesse J, Gelderblom, Hans, Cats, Annemieke, Guchelaar, Henk-Jan, Schellens, Jan H M

“…Fluoropyrimidine treatment can result in severe toxicity in up to 30% of patients and is often the result of reduced activity of the key metabolic enzyme…”
Get full text

A Genome‐Wide Association Study of Endoxifen Serum Concentrations and Adjuvant Tamoxifen Efficacy in Early‐Stage Breast Cancer Patients by Sanchez‐Spitman, Anabel Beatriz, Böhringer, Stefan, Dezentjé, Vincent Olaf, Gelderblom, Hans, Swen, Jesse Joachim, Guchelaar, Henk‐Jan

“…Tamoxifen is part of the standard of care of endocrine therapy for adjuvant treatment of breast cancer. However, survival outcomes with tamoxifen are highly…”
Get full text

Exposure–response analysis of endoxifen serum concentrations in early-breast cancer by Sanchez-Spitman, Anabel Beatriz, Moes, Dirk-Jan A. R., Swen, Jesse J., Dezentjé, Vincent O., Lambrechts, Diether, Neven, Patrick, Gelderblom, Hans, Guchelaar, Henk-Jan

“…Purpose Tamoxifen is part of endocrine therapy in breast cancer treatment. Studies have indicated the use of endoxifen concentrations, tamoxifen active…”
Get full text

Clinical Implications of CYP2D6 Genotyping in Tamoxifen Treatment for Breast Cancer by Dezentjé, Vincent O, Guchelaar, Henk-Jan, Nortier, Johan W R, van de Velde, Cornelis J H, Gelderblom, Hans

“…In October 2006 the Food and Drug Administration recommended an update in the tamoxifen label to reflect the increased risk of recurrence in breast cancer…”
Get full text

Real-world data of HER2-low metastatic breast cancer: A population based cohort study by Holthuis, Emily I., Vondeling, Gerard T., Kuiper, Josephina G., Dezentjé, Vincent, Rosenlund, Mats, Overbeek, Jetty A., van Deurzen, Carolien H.M.

“…With the introduction of investigational human epidermal growth factor receptor 2 (HER2) targeting treatments, thorough understanding of breast cancer with…”
Get full text

Tamoxifen Metabolism and Efficacy in Breast Cancer: A Prospective Multicenter Trial by Neven, Patrick, Jongen, Lynn, Lintermans, Anneleen, Van Asten, Kathleen, Blomme, Chantal, Lambrechts, Diether, Poppe, An, Wildiers, Hans, Dieudonné, Anne-Sophie, Brouckaert, Olivier, Decloedt, Jan, Berteloot, Patrick, Verhoeven, Didier, Joerger, Markus, Vuylsteke, Peter, Wynendaele, Wim, Casteels, Minne, Van Huffel, Sabine, Lybaert, Willem, Van Ginderachter, Johan, Paridaens, Robert, Vergote, Ignace, Dezentjé, Vincent Olaf, Van Calster, Ben, Guchelaar, Henk-Jan

“…Levels of endoxifen, the most active metabolite of tamoxifen, vary by the highly polymorphic cytochrome P450 (CYP) 2D6 enzyme. We prospectively investigated…”
Get full text

A cost analysis of upfront DPYD genotype–guided dose individualisation in fluoropyrimidine-based anticancer therapy by Henricks, Linda M., Lunenburg, Carin A.T.C., de Man, Femke M., Meulendijks, Didier, Frederix, Geert W.J., Kienhuis, Emma, Creemers, Geert-Jan, Baars, Arnold, Dezentjé, Vincent O., Imholz, Alexander L.T., Jeurissen, Frank J.F., Portielje, Johanna E.A., Jansen, Rob L.H., Hamberg, Paul, ten Tije, Albert J., Droogendijk, Helga J., Koopman, Miriam, Nieboer, Peter, van de Poel, Marlène H.W., Mandigers, Caroline M.P.W., Rosing, Hilde, Beijnen, Jos H., van Werkhoven, Erik, van Kuilenburg, André B.P., van Schaik, Ron H.N., Mathijssen, Ron H.J., Swen, Jesse J., Gelderblom, Hans, Cats, Annemieke, Guchelaar, Henk-Jan, Schellens, Jan H.M.

“…Fluoropyrimidine therapy including capecitabine or 5-fluorouracil can result in severe treatment-related toxicity in up to 30% of patients. Toxicity is often…”
Get full text

Integrated analysis of pain, health-related quality of life, and analgesic use in patients with metastatic castration-resistant prostate cancer treated with Radium-223 by Badrising, Sushil K., Louhanepessy, Rebecca D., van der Noort, Vincent, Kieffer, Jacobien, Coenen, Jules L. L. M., Hamberg, Paul, Beeker, Aart, Wagenaar, Nils, Lam, Marnix, Celik, Filiz, Loosveld, Olaf J. L., Oostdijk, Ad, Zuetenhorst, Hanneke, de Feijter, Jeantine M., Dezentjé, Vincent O., Ras-van Spijk, Suzan, Vegt, Erik, Haanen, John B., van de Poll-Franse, Lonneke V., Zwart, Wilbert, Bergman, Andries M.

“…Background Radium-223 (Ra-223), an alpha-emitting radiopharmaceutical, established an improved overall survival and health-related quality of life (HRQoL) in…”
Get full text

Severe fluoropyrimidine toxicity due to novel and rare DPYD missense mutations, deletion and genomic amplification affecting DPD activity and mRNA splicing by van Kuilenburg, André B.P., Meijer, Judith, Maurer, Dirk, Dobritzsch, Doreen, Meinsma, Rutger, Los, Maartje, Knegt, Lia C., Zoetekouw, Lida, Jansen, Rob L.H., Dezentjé, Vincent, van Huis-Tanja, Lieke H., van Kampen, Roel J.W., Hertz, Jens Michael, Hennekam, Raoul C.M.

“…Dihydropyrimidine dehydrogenase (DPD) is the initial and rate-limiting enzyme in the catabolism of 5-fluorouracil (5FU). Genetic variations in DPD have emerged…”
Get full text

Model-Informed Development of a Cost-Saving Dosing Regimen for Sacituzumab Govitecan by Moes, Dirk J. A. R., Hendrikx, Jeroen J. M. A., Guchelaar, Henk-Jan, Mathijssen, Ron H. J., Bakker, J. L., Dezentjé, Vincent O., de Rouw, Nikki, van Erp, Nielka P., Smit, Egbert F., van den Heuvel, Michel M., Munnink, Thijs H. Oude, van Kats, Maartje, Croes, Sander, Kroep, Judith R., Zwaveling, Juliette, ter Heine, Rob

“…Background The antibody–drug conjugate sacituzumab govitecan is approved for metastatic triple-negative breast cancer and has shown promising results in…”
Get full text

Toxicity of dual HER2-blockade with pertuzumab added to anthracycline versus non-anthracycline containing chemotherapy as neoadjuvant treatment in HER2-positive breast cancer: The TRAIN-2 study by van Ramshorst, Mette S, van Werkhoven, Erik, Honkoop, Aafke H, Dezentjé, Vincent O, Oving, Irma M, Mandjes, Ingrid A, Kemper, Inge, Smorenburg, Carolien H, Stouthard, Jacqueline M, Linn, Sabine C, Sonke, Gabe S

“…Abstract Background The addition of pertuzumab to neoadjuvant trastuzumab-based chemotherapy improves pathologic complete response rates in HER2-positive…”
Get full text

Phase 1 Study to Evaluate the Safety of Reducing the Prophylactic Dose of Dexamethasone around Docetaxel Infusion in Patients with Prostate and Breast Cancer by Lugtenberg, Rieneke T, de Groot, Stefanie, Houtsma, Danny, Dezentjé, Vincent O, Vulink, Annelie J E, Fischer, Maarten J, Portielje, Johanneke E A, van der Hoeven, Jacobus J M, Gelderblom, Hans, Pijl, Hanno, Kroep, Judith R

“…There is little evidence that supports the registered high dose of dexamethasone used around docetaxel. However, this high dose is associated with considerable…”
Get full text

RNA Biomarkers as a Response Measure for Survival in Patients with Metastatic Castration-Resistant Prostate Cancer by Boerrigter, Emmy, Benoist, Guillemette E, van Oort, Inge M, Verhaegh, Gerald W, de Haan, Anton F J, van Hooij, Onno, Groen, Levi, Smit, Frank, Oving, Irma M, de Mol, Pieter, Smilde, Tineke J, Somford, Diederik M, Hamberg, Paul, Dezentjé, Vincent O, Mehra, Niven, van Erp, Nielka P, Schalken, Jack A

“…Treatment evaluation in metastatic castration-resistant prostate cancer is challenging. There is an urgent need for biomarkers to discriminate short-term…”
Get full text